Puma Bio stock: buy or sell?

PBYI stock price: $11.71 -2.01% At close on May 22nd, 2020

Updated on:
May 22nd, 2020


Shares of Puma Biotechnology closed on Friday at $11.71 and eased a rough -2.01%. On Tuesday PBYI collapsed a frightening -10.05%. On May 13th PBYI skyrocketed a dazzling 7.18%.

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care.

Should I buy Puma Bio stock?

Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best time to buy them. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Puma Bio stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean PBYI will fall in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Puma Bio stock a buy?

Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for PBYI stock for the last 30 days.

Puma Bio stock analysis

Daily outlook

Puma Bio eased a rough -2.01% and closed at $11.71.

Puma Biotechnology shares eased -2.01% to $11.71 on Friday. Since SMA100d and SMA200d crossed up on Apr 30th, PBYI price climbed $1.66 per share (16.52%). Since price and SMA200d lines crossed up on Apr/17, PBYI climbed $3.11 (36.16%).

PBYI stock chart (daily)

Weekly outlook

After boosting a super good 12.18% in a week by mid May, Puma Bio closed this week at $11.71 and plunged a scary -7.36%.

Puma Bio stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Late April, SMA20w and SMA40w crossed up triggering a rise of 21.35%. Since mid April when PBYI stock price broke up the SMA40w line, it gained $3.72 (46.56%).

PBYI stock chart (weekly)

Puma Bio stock price history

Puma Bio stock went public on April 24th, 2012 with a price of $13.001. Since then, PBYI stock declined a -9.90%, with a yearly average of -1.20%.

1: Adjusted price after possible price splits or reverse-splits.

Puma Bio stock historical price chart

PBYI stock reached 52-week highs at $16.35, and all-time highs 2014-08-26 with a price of 279.37.

Puma Bio stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' PBYI stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price forecast for Puma Biotechnology stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

, Puma Bio failed to meet the estimates of the experts and posted a tragic EPS of $-0.80 per share when experts were expecting $-0.92.
PBYI earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Puma Bio annual revenues climbed an amazing 806.60% to $250.99 million dollars from $27.69 marked in 2017. In the same way, its earnings margin (compared to sales) rocketed to -45.25%, that is $-113.58 million.

PBYI annual Sales and Income evolution
2017$28 M-$-291.96 M-1054.6%-
2018$251 M806.60%$-113.58 M-45.3%-61.10%

Quarterly financial results

Puma Bio reported $71.08 M in sales for 2018-Q4, a 13.49% up compared to previous quarter. Reported quarter income marked $-30.70 million with a profit margin of -43.18%. Profit margin plummed a -20.51% compared to previous quarter when profit margin was -22.67%. When comparing turnover to same quarter last year, Puma Biotechnology sales marked an exceptional increase and skyrocketed a 228.95%. Looking back to recent quarterly results, Puma Biotechnology posted 2 negative quarters in a row.
PBYI quarterly Sales and Income evolution
2017-Q3$6 M-$-77.18 M-1269.4%-
2017-Q4$22 M255.39%$-64.08 M-296.5%-16.98%
2018-Q1$67 M207.83%$-24.35 M-36.6%-62.01%
2018-Q2$51 M-23.68%$-44.34 M-87.3%82.11%
2018-Q3$63 M23.37%$-14.20 M-22.7%-67.97%
2018-Q4$71 M13.49%$-30.70 M-43.2%116.15%

Puma Bio ownership

When you are planning to invest in shares of a company, it's worth to check its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Puma Biotechnology, 11.59% of all outstanding shares are owned by its staff.

Bearish positions for PBYI stock account 0.00%, no big difference from last month.

For a better understanding, the following table shows ownership data compared to other related companies:

Market cap$460.9 M
Total shares39.4 M
Float shares31.7 M
  - Institutional holdings (%)88.8%
  - Insider holdings (%)11.6%
Shares in short selling0.0%

Puma Bio summary

Friday, May 22nd, 2020
Day range$11.47 - $11.94
Previous close$11.95
Session gain-2.01%
Average true range$1.21
50d mov avg$9.57
100d mov avg$9.87
200d mov avg$9.57
Daily pattern
Weekly pattern lt06a

Puma Bio performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Puma Bio, the comparison is made against .
PBYIPuma Biotechnolog...-13.90%27.84%-24.21%

Puma Bio competitors

Unfortunately, we could not find any public company that could be defined as Puma Bio competitor. This doesn't mean Puma Bio does not have any competitor in the market, it's just we could not detected it.